K-ras mutations in the bile of patients with primary sclerosing cholangitis

Area of Science:

• Gastroenterology and Hepatology
• Oncology
• Molecular Biology

Background:

• Cholangiocarcinoma (CCC) is a complication of primary sclerosing cholangitis (PSC).
• Identifying PSC patients at high risk for CCC is challenging.
• Early diagnosis of CCC in PSC patients is difficult.

Purpose of the Study:

• To investigate K-ras mutations in bile fluid as potential early molecular markers for cholangiocarcinoma in PSC patients.
• To assess the value of K-ras mutations as a risk factor for cholangiocarcinogenesis.
• To explore implications for liver transplantation timing.

Main Methods:

• K-ras mutations analyzed using polymerase chain reaction/restriction fragment length polymorphism in bile fluid.
• Study included 56 PSC patients and 20 patients with other cholestatic diseases.
• Prospective investigation over a mean follow-up period of 31.5 months.

Main Results:

• K-ras mutations were found in 30% of PSC patients (17/56).
• No significant difference in mean Mayo score between PSC patients with and without K-ras mutations.
• During follow-up, 4 CCCs and 2 dysplasias were diagnosed in PSC patients with K-ras mutations (p<0.001).

Conclusions:

• K-ras mutations in bile fluid are frequent early events in cholangiocarcinogenesis for PSC patients.
• These mutations are not specific for malignancy and can occur in normal or dysplastic bile duct mucosa.
• K-ras mutations in bile fluid of PSC patients are risk factors for CCC development, impacting liver transplant timing but not for direct diagnosis.